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Abstract: The cannabinoid receptor type 2 (CB2) has a very low expression level in brain tissue under basal
conditions, but it is up-regulated in diverse pathological conditions. Two promising lead structures from the
literature, N-((3S,5S,7S)-adamantan-1-yl)-8-methoxy-4-oxo-1-pentyl-1,4-dihydroquinoline-3-carboxamide and
8-butoxy-N-(2-fluoro-2-phenylethyl)-7-methoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide – designated KD2
and KP23, respectively – were evaluated as potential PET ligands for imaging CB2. Both KD2 and KP23 were
synthesized and labeled with carbon-11. In vitro autoradiographic studies on rodent spleen tissues showed
that [
11
C]KD2 exhibits superior properties. A pilot study using [
11
C]KD2 on human post mortem ALS spinal cord
slices indicated high CB2 expression level and specific binding, a very exciting finding if considering the future
diagnostic application of CB2 ligands and their utility in therapy monitoring. In vivo blocking studies in rats with
[
11
C]KD2 showed also high specific uptake in spleen tissue. Although the protein-bound fraction is relatively high,
KD2 or KD2 derivatives could be very useful tools for the non-invasive investigation of CB2 levels under various
neuroinflammatory conditions.
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1. Introduction
Cannabinoid receptor types 1 (CB1)
and 2 (CB2) were discovered about 30
years ago as G protein-coupled receptors
containing seven transmembrane spanning
domains. CB1 is expressed throughout
the body, but mainly in brain regions
(cerebellum, basal ganglia, hippocampus,
and neocortex). CB2 is predominantly
expressed on cells related to the immune
system (spleen, lymphocytes) and also
on keratinocytes. The presence of CB2
in the central nervous system has been
controversially discussed in literature since
1996.
[1]
Today CB2 is generally accepted
to be present in brain tissues, although in
very low concentrations.
However, under neuroinflammatory
conditions, a CB2 level increase is
observed. For instance in the brain of
Alzheimer patients where activated
microglia cluster at β-amyloid plaques.
[2–5]
CB2 increase is also reported for the rat
chronic lesion model of Huntington’s
disease, especially in the striatum.
[6]
Furthermore, both hypoxia-ischemia and
middle cerebral artery occlusion induced
an up-regulation in the expression of CB2
in proliferating microglia in rat brain.
[7]
Increased CB2 levels were also reported in
post mortem spinal cord of human patients
of Amyotrophic Lateral Sclerosis (ALS)
and corresponding mouse models and
Multiple Sclerosis.
[4,8]
A large number of structurally diverse
CB2 ligands have been synthesized
and characterized in the past decade.
[9]
Among all these classes of CB2 ligands,
2-oxoquinoline and 4-quinolone-3-
carboxamide derivatives appear to be the
most efficient inverse agonists, with high
binding affinity and selectivity towards
CB2. Currently, there are no PET (positron
emission tomography) ligands for imaging
CB2 expression in humans.A suitable PET
radioligand for imaging CB2 would be an
invaluable research tool to explore the role
of CB2 receptor expression in peripheral
and/or central inflammatory disorders.
Herein, we report the in vitro/in
vivo evaluation of two oxo-quinoline
derivatives, designated [
11
C]KD2 and
[
11
C]KP23, as potential radiotracers for
imaging CB2 receptor by PET.
2. Synthesis and Radiolabeling
2.1 Synthesis of KD2
The synthesis of the reference
compound, KD2, followed synthetic
pathways already described.
[10]
In brief,
the quinoline structure 2 was prepared
via the Gould–Jacobs reaction as outlined
in Scheme 1 by reacting anisidine with
diethyl 2-(ethoxymethylene)malonate
and subsequent benzannulation at
high temperature. N-alkylation with
1-bromopentane followed by hydrolysis of
the ethyl ester gave the free quinoline acid
4, which was coupled to aminoadamantane
using HBTU as the coupling reagent to
yield KD2. Phenolic precursor compound
5 for radiolabeling was synthesized from
the reference compound by demethylation
using boron tribromide.
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2.2 Synthesis of KP23
The synthesis of the non-radioactive
reference compound, KP23, was
accomplished based on the modified
procedure described by Turkman et al.
[11]
as outlined inScheme2.Briefly, compound
7 was obtained by aromatic nitration
of 3-hydroxy-4-methoxybenzaldehyde
(6) with nitric acid. O-alkylation with
1-bromobutane afforded intermediate 8.
Reduction using iron powder followed by
reaction in situ with dimethyl malonate
yielded compound 9. Hydrolysis under
basic conditions to the free acid 10 and
amide bond formation using 2-fluoro-2-
phenylethanamine free base led to the final
reference compound KP23. The phenolic
precursor 11 for radiolabeling was directly
synthesized from KP23 by demethylation
using lithium chloride.
2.3 Radiolabeling Procedure
The phenolic precursor 5 or 11, was
reacted with [
11
C]-methyl iodide to afford
[
11
C]KD2 or [
11
C]KP23, respectively
(Scheme 3). Both tracers were obtained
in 99% radiochemical purity after semi-
HPLC purification in yields of 2–5 GBq.
The total radiolabeling time was around
40 min after [
11
C]CO
2
delivery from the
cyclotron. Specific activity was high and
ranged from 80 to 350 GBq/µmol at the
end of synthesis.
3. in vitro/in vivo Evaluation
3.1 Autoradiography Experiments
To confirm specificity of binding of the
radiotracers, rat and mouse spleens known
to have a high physiological expression of
CB2 were investigated in autoradiography
experiments (Fig. 1). Specific binding of
[
11
C]KD2 and [
11
C]KP23 was determined
in blocking experiments (B1, B2) using the
CB2 specific partial agonist GW405833 in
5000-fold excess.
Although high in vitro specific binding
was observed for both radiotracers, [
11
C]
KD2 showed superior properties and has
greater potential to become a successful
PET tracer. Consequently, we selected
[
11
C]KD2 for further evaluation in vitro
and in vivo.
In a preliminary autoradiographic
study, we investigated whether [
11
C]KD2
binds to human post mortem ALS spinal
cord slices, as literature reports suggest
CB2 overexpression in the spinal cord
of ALS patients.
[12–14]
Fig. 2 confirms
not only the presence of CB2 but also
specific binding of [
11
C]KD2. These are
encouraging results towards non-invasive
imaging of CB2 in ALS patients.
To excludeKD2as a substrate for efflux
transporter P-gp within the blood brain
barrier, the permeation of [
11
C]KD2 across
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Radiosynthetic
scheme towards
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C]KD2 and
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C]KP23.
Fig. 1. A) 0.6 nM
[
11
C]KD2 or
[
11
C]KP23 on rat
(A1) and mouse (A2)
spleen. B) Blocking
with 5 µM GW405833
on rat (B1) and mouse
(B2) spleen.
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MDCK cells transfected with human P-gp
was investigated. The respective ratio for
[
11
C]KD2 of the transport basal to apical
and apical to basal, respectively, was 0.5,
indicating no net efflux transport by P-gp.
Lipophilicity (logD) as an important
physicochemical attribute for a CNS
penetrating compound was determined by
the shake-flask method in octanol/buffer
at pH 7.4.
[15]
The logD value of [
11
C]KD2
was found to be 3.29 ± 0.04 (n = 6), and
suggested that [
11
C]KD2 would be a good
blood-brain barrier penetrant.
The free fraction of [
11
C]KD2 in
human plasma was determined in a protein
binding assay displaying a free fraction
f
u
of 0.001 and in 4% BSA 0.017. These
findings were confirmed in an equilibrium
dialysis experiment. The low free fraction
is probably a consequence of the relatively
high lipophilicity of [
11
C]KD2. Increase
of free fraction could be subject of future
optimization.
3.2 in vivo PET studies
PET scans with Wistar rats showed
high accumulation of [
11
C]KD2 in liver,
spleen and intestine. The accumulation in
spleen was displaced by injection of the
CB2 specific partial agonist GW405833
(1.5 mg/kg), indicating in vivo specific
binding (Fig. 3).As expected, radioactivity
in the brain was significantly lower than
in the periphery (data not shown). Uptake
in pons and cerebellum was higher than
in hippocampus and caudate/putamen, in
agreement with the expression pattern of
CB2 in the rat brain.
[16–18]
We are currently investigating the
utility of [
11
C]KD2 in mouse models of
neuroinflammation where CB2 receptors
are upregulated, e.g. the lipopolysaccharide
LPS mouse model as described by Qin et
al.
[19,20]
4. Conclusion
In the process of developing a
suitable CNS radiotracer for imaging
CB2 receptors we evaluated the potential
of two lead compounds KD2 and KP23.
We have established the syntheses of
non-radioactive reference compounds
using modified synthetic routes based
on literature procedures. A robust and
reliable radiosynthetic procedure for both
novel CB2 radiotracers, [
11
C]KD2 and
[
11
C]KP23, was established and afforded
products with high specific activity,
high radiochemical yields and excellent
radiochemical purity of ≥99%. In vitro
autoradiography of both radiotracers on
rodent spleen tissues and post mortem
ALS spinal cord slices indicated specific
binding to CB2. The results from the pilot
study using human post mortem ALS
spinal cord tissue sections showing high
CB2 expression level are very exciting
if one considers the future diagnostic
application of CB2 ligands and their utility
in therapy monitoring. Specific uptake into
spleen tissue was also observed in dynamic
PET studies using Wistar rats. [
11
C]KD2
is a very promising radiotracer for CB2,
but with good potential for improvement
towards reduced protein binding. The
syntheses of KD2 derivatives with
improved physicochemical properties are
currently ongoing in our laboratory.
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Fig. 2. In vitro autoradiography with slices from
cervical spinal cord from two ALS patients.
Incubation with 0.2 nM [
11
C]KD2 in the absence
(a) and presence (b) of 1 μM GW405833.
Fig. 3. Time activity curves of [
11
C]KD2 from an in vivo displacement PET study. CB2 selective
GW4058233 was injected i.v. from 15 to 16 min (dashed lines) after injection of 20 MBq [
11
C]KD2.
